CERT logo

Certara (CERT) Stock

Profile

Sector:

Healthcare

Country:

United States

IPO:

11 December 2020

Indexes:

Not included

Description:

Certara is a global leader in biosimulation and drug development. They provide software and consulting services to optimize the drug development process, helping pharmaceutical companies make informed decisions, reduce costs, and bring new therapies to market faster. Their expertise enhances research and development efficiency in the life sciences.

Events Calendar

Earnings

Next earnings date:

Feb 28, 2025

Recent quarterly earnings:

Nov 06, 2024

Recent annual earnings:

Feb 29, 2024
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

N/A

Analyst ratings

Recent major analysts updates

07 Nov '24 Barclays
Equal-Weight
05 Nov '24 Baird
Neutral
15 Oct '24 Barclays
Equal-Weight
27 Sept '24 UBS
Buy
07 Aug '24 UBS
Neutral
07 Aug '24 Baird
Neutral
11 July '24 Keybanc
Overweight
10 July '24 JMP Securities
Market Perform
28 June '24 Barclays
Equal-Weight
10 Apr '24 Keybanc
Overweight

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Efficiency

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Institutional Ownership

Certara Reports Third Quarter 2024 Financial Results
Certara Reports Third Quarter 2024 Financial Results
Certara Reports Third Quarter 2024 Financial Results
CERT
globenewswire.com06 November 2024

RADNOR, Pa., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today reported its financial results for the third quarter of fiscal year 2024.

Certara Appoints John Reynders as New Independent Board Member
Certara Appoints John Reynders as New Independent Board Member
Certara Appoints John Reynders as New Independent Board Member
CERT
globenewswire.com16 October 2024

RADNOR, Pa., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced the appointment of John Reynders, PhD, to its Board of Directors, effective October 15, 2024.

Certara Completes Acquisition of Chemaxon
Certara Completes Acquisition of Chemaxon
Certara Completes Acquisition of Chemaxon
CERT
globenewswire.com02 October 2024

Certara completes acquiring Chemaxon, a leading cheminformatics company that develops scientific informatics software used by the life sciences industry.

Certara to Participate in Upcoming Investor Conferences
Certara to Participate in Upcoming Investor Conferences
Certara to Participate in Upcoming Investor Conferences
CERT
globenewswire.com21 August 2024

RADNOR, Pa., Aug. 21, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that Company management will participate in the following investor conferences:

Certara Launches Phoenix™ Version 8.5 Drug Development Software
Certara Launches Phoenix™ Version 8.5 Drug Development Software
Certara Launches Phoenix™ Version 8.5 Drug Development Software
CERT
globenewswire.com15 August 2024

RADNOR, Pa., Aug. 15, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced the launch of Phoenix™ version 8.5.

Certara, Inc. (CERT) Q2 Earnings and Revenues Lag Estimates
Certara, Inc. (CERT) Q2 Earnings and Revenues Lag Estimates
Certara, Inc. (CERT) Q2 Earnings and Revenues Lag Estimates
CERT
zacks.com06 August 2024

Certara, Inc. (CERT) came out with quarterly earnings of $0.07 per share, missing the Zacks Consensus Estimate of $0.11 per share. This compares to earnings of $0.12 per share a year ago.

Certara Reports Second Quarter 2024 Financial Results
Certara Reports Second Quarter 2024 Financial Results
Certara Reports Second Quarter 2024 Financial Results
CERT
globenewswire.com06 August 2024

RADNOR, Pa., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today reported its financial results for the second quarter of fiscal year 2024.

Certara to Acquire Chemaxon to Strengthen Drug Discovery Software Portfolio
Certara to Acquire Chemaxon to Strengthen Drug Discovery Software Portfolio
Certara to Acquire Chemaxon to Strengthen Drug Discovery Software Portfolio
CERT
globenewswire.com09 July 2024

Combined organization brings broader predictive capabilities to drug discovery at scale Reiterates full year 2024 guidance RADNOR, Pa., July 09, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced it has signed a definitive agreement to acquire Chemaxon, a leading provider of cheminformatics software.

Certara to Report Second Quarter 2024 Financial Results on August 6th, 2024
Certara to Report Second Quarter 2024 Financial Results on August 6th, 2024
Certara to Report Second Quarter 2024 Financial Results on August 6th, 2024
CERT
globenewswire.com02 July 2024

RADNOR, Pa., July 02, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that it will release financial results for the second quarter of 2024 after the market close on Tuesday, August 6th, 2024. Company management will host a conference call to discuss financial results at 5:00PM ET.

Certara to Participate in the Jefferies Global Healthcare Conference
Certara to Participate in the Jefferies Global Healthcare Conference
Certara to Participate in the Jefferies Global Healthcare Conference
CERT
globenewswire.com29 May 2024

RADNOR, Pa., May 29, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that Company management will participate in the Jefferies Global Healthcare Conference.

  • 1(current)
  • 2
  • 1(current)
  • 2

FAQ

  • What is the primary business of Certara?
  • What is the ticker symbol for Certara?
  • Does Certara pay dividends?
  • What sector is Certara in?
  • What industry is Certara in?
  • What country is Certara based in?
  • When did Certara go public?
  • Is Certara in the S&P 500?
  • Is Certara in the NASDAQ 100?
  • Is Certara in the Dow Jones?
  • When was Certara's last earnings report?
  • When does Certara report earnings?
  • Should I buy Certara stock now?

What is the primary business of Certara?

Certara is a global leader in biosimulation and drug development. They provide software and consulting services to optimize the drug development process, helping pharmaceutical companies make informed decisions, reduce costs, and bring new therapies to market faster. Their expertise enhances research and development efficiency in the life sciences.

What is the ticker symbol for Certara?

The ticker symbol for Certara is NASDAQ:CERT

Does Certara pay dividends?

No, Certara does not pay dividends

What sector is Certara in?

Certara is in the Healthcare sector

What industry is Certara in?

Certara is in the Health Information Services industry

What country is Certara based in?

Certara is headquartered in United States

When did Certara go public?

Certara's initial public offering (IPO) was on 11 December 2020

Is Certara in the S&P 500?

No, Certara is not included in the S&P 500 index

Is Certara in the NASDAQ 100?

No, Certara is not included in the NASDAQ 100 index

Is Certara in the Dow Jones?

No, Certara is not included in the Dow Jones index

When was Certara's last earnings report?

Certara's most recent earnings report was on 6 November 2024

When does Certara report earnings?

The next expected earnings date for Certara is 28 February 2025

Should I buy Certara stock now?

As of today, analysts generally recommend a 'Buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions